Diagnostic and prognostic potential of serum MIR-7, MIR-16, MIR-25, MIR-93, MIR-182, MIR-376a and MIR-429 in ovarian cancer patients

British Journal of Cancer

Volumn 113, Issue 9, 2015, Pages 1358-1366

  Meng, Xiaodan ^a   Joosse, Simon A ^a   Müller, Volkmar ^a   Trillsch, Fabian ^a   Milde Langosch, Karin ^a   Mahner, Sven ^a   Geffken, Maria ^a   Pantel, Klaus ^a   Schwarzenbach, Heidi ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; MICRORNA; MICRORNA 16; MICRORNA 182; MICRORNA 25; MICRORNA 376A; MICRORNA 429; MICRORNA 7; MICRORNA 93; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; BLOOD LEVEL; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DOWN REGULATION; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVARIAN CANCER CELL LINE; OVARY CARCINOMA; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PREDICTOR VARIABLE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; UPREGULATION; BLOOD; CASE CONTROL STUDY; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BIOMARKERS, TUMOR; CA-125 ANTIGEN; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MICRORNAS; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; UP-REGULATION;

EID: 84946499684     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.340     Document Type: Article

References (45)

1. Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136(2): 215-233.
2. Chen J, Wang L, Matyunina LV, Hill CG, McDonald JF (2011) Overexpression of miR-429 induces mesenchymal-to-epithelial transition (MET) in metastatic ovarian cancer cells. Gynecol Oncol 121(1): 200-205.
3. Cheng AM, Byrom MW, Shelton J, Ford LP (2005) Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res 33(4): 1290-1297.
4. Cui J (2015) MiR-16 family as potential diagnostic biomarkers for cancer: A systematic review and meta-analysis. Int J Clin Exp Med 8(2): 1703-1714.
5. Davidson B, Tropé CG, Reich R (2014) The clinical and diagnostic role of microRNAs in ovarian carcinoma. Gynecol Oncol 133(3): 640-646.
6. Eichelser C, Stückrath I, Müller V, Milde-Langosch K, Wikman H, Pantel K, Schwarzenbach H (2014) Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. Oncotarget 5(20): 9650-9663.
7. Foekens JA, Sieuwerts AM, Smid M, Look MP, de Weerd V, Boersma AW, Klijn JG, Wiemer EA, Martens JW (2008) Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci USA 105(35): 13021-13026.
8. Formosa A, Markert EK, Lena AM, Italiano D, Finazzi-Agro E, Levine AJ, Bernardini S, Garabadgiu AV, Melino G, Candi E (2014) MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells. Oncogene 33(44): 5173-5182.
9. Ge W, Yu DC, Li QG, Chen X, Zhang CY, Ding YT (2014) Expression of serum miR-16, let-7f, and miR-21 in patients with hepatocellular carcinoma and their clinical significances. Clin Lab 60(3): 427-434.
10. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ (2008) The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10(5): 593-601.
11. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ (2010) Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg 251(3): 499-505.
12. Hu X, Macdonald DM, Huettner PC, Feng Z, El Naqa IM, Schwarz JK, Mutch DG, Grigsby PW, Powell SN, Wang X (2009a) A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol 114(3): 457-464.
13. Hu X, Macdonald DM, Huettner PC, Feng Z, El Naqa IM, Schwarz JK, Mutch DG, Grigsby PW, Powell SN, Wang X (2009b) A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol 114(3): 457-464.
14. Hu Z, Dong J, Wang LE, Ma H, Liu J, Zhao Y, Tang J, Chen X, Dai J, Wei Q, Zhang C, Shen H (2012) Serum microRNA profiling and breast cancer risk: The use of miR-484/191 as endogenous controls. Carcinogenesis 33(4): 828-834.
15. Huang XY, Yao JG, Huang HD, Wang C, Ma Y, Xia Q, Long XD (2013) MicroRNA-429 modulates hepatocellular carcinoma prognosis and tumorigenesis. Gastroenterol Res Pract 2013: 804128.
16. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA (2014) Ovarian cancer. Lancet 384(9951): 1376-1388.
17. Ji T, Zheng ZG, Wang FM, Xu LJ, Li LF, Cheng QH, Guo JF, Ding XF (2014) Differential microRNA expression by Solexa sequencing in the sera of ovarian cancer patients. Asian Pac J Cancer Prev 15(4): 1739-1743.
18. Joosse SA, Muller V, Steinbach B, Pantel K, Schwarzenbach H (2014) Circulating cell-free cancer-testis MAGE-A RNA, BORIS RNA, let-7b and miR-202 in the blood of patients with breast cancer and benign breast diseases. Br J Cancer 111(5): 909-917.
19. Kalinowski FC, Brown RAM, Ganda C, Giles KM, Epis MR, Horsham J, Leedman PJ (2014) microRNA-7: A tumor suppressor miRNA with therapeutic potential. Int J Biochem Cell Biol 54(0): 312-317.
20. Kim VN (2005) MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 6(5): 376-385.
21. Komatsu S, Ichikawa D, Hirajima S, Kawaguchi T, Miyamae M, Okajima W, Ohashi T, Arita T, Konishi H, Shiozaki A, Fujiwara H, Okamoto K, Yagi N, Otsuji E (2014) Plasma microRNA profiles: identification of miR-25 as a novel diagnostic and monitoring biomarker in oesophageal squamous cell carcinoma. Br J Cancer 111(8): 1614-1624.
22. Li BS, Zuo QF, Zhao YL, Xiao B, Zhuang Y, Mao XH, Wu C, Yang SM, Zeng H, Zou QM, Guo G (2015) MicroRNA-25 promotes gastric cancer migration, invasion and proliferation by directly targeting transducer of ERBB2, 1 and correlates with poor survival. Oncogene 34(20): 2556-2565.
23. Li J, Du L, Yang Y, Wang C, Liu H, Wang L, Zhang X, Li W, Zheng G, Dong Z (2013) MiR-429 is an independent prognostic factor in colorectal cancer and exerts its anti-apoptotic function by targeting SOX2. Cancer Lett 329(1): 84-90.
24. McDermott AM, Kerin MJ, Miller N (2013) Identification and validation of miRNAs as endogenous controls for RQ-PCR in blood specimens for breast cancer studies. PLoS One 8(12): e83718.
25. Meinhold-Heerlein I, Hauptmann S (2014) The heterogeneity of ovarian cancer. Arch Gynecol Obstet 289(2): 237-239.
26. Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH, Kim JW, Kim S (2008a) MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 14(9): 2690-2695.
27. Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH, Kim JW, Kim S (2008b) MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 14(9): 2690-2695.
28. Navarro A, Diaz T, Tovar N, Pedrosa F, Tejero R, Cibeira MT, Magnano L, Rosinol L, Monzo M, Blade J, Fernandez de Larrea C (2015) A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma. Oncotarget 6(3): 1874-1883.
29. Schwarzenbach H, Hoon DS, Pantel K (2011) Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11(6): 426-437.
30. Simpson RJ, Lim JW, Moritz RL, Mathivanan S (2009) Exosomes: proteomic insights and diagnostic potential. Expert Rev Proteomics 6(3): 267-283.
31. Smith AL, Iwanaga R, Drasin DJ, Micalizzi DS, Vartuli RL, Tan AC, Ford HL (2012) The miR-106b-25 cluster targets Smad7, activates TGF-[beta] signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer. Oncogene 31(50): 5162-5171.
32. Stuckrath I, Rack B, Janni W, Jager B, Pantel K, Schwarzenbach H (2015) Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients. Oncotarget 6(15): 13387-13401.
33. Sun Y, Shen S, Liu X, Tang H, Wang Z, Yu Z, Li X, Wu M (2014) MiR-429 inhibits cells growth and invasion and regulates EMT-related marker genes by targeting Onecut2 in colorectal carcinoma. Mol Cell Biochem 390(1-2): 19-30.
34. Suto T, Yokobori T, Yajima R, Morita H, Fujii T, Yamaguchi S, Altan B, Tsutsumi S, Asao T, Kuwano H (2015) MicroRNA-7 expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity via EGFR regulation. Carcinogenesis 36(3): 338-345.
35. Theriault BL, Basavarajappa HD, Lim H, Pajovic S, Gallie BL, Corson TW (2014) Transcriptional and epigenetic regulation of KIF14 overexpression in ovarian cancer. PLoS One 9(3): e91540.
36. Wagner U, Harter P, Hilpert F, Mahner S, Reuss A, du Bois A, Petru E,Meier W, Ortner P, Konig K, Lindel K, Grab D, Piso P, Ortmann O, Runnebaum I, Pfisterer J, Luftner D, Frickhofen N, Grunwald F, Maier BO, Diebold J, Hauptmann S, Kommoss F, Emons G, Radeleff B, Gebhardt M, Arnold N, Calaminus G, Weisse I, Weis J, Sehouli J, Fink D, Burges A, Hasenburg A, Eggert C (2013) S3-guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours short version 1.0-AWMF registration number: 032/035OL. June 2013. Geburtshilfe Frauenheilkd 73(9): 874-889.
37. Wang H,Wang L,Wu Z, Sun R, Jin H, Ma J, Liu L, Ling R, Yi J,Wang L, Bian J, Chen J, Li N, Yuan S, Yun J (2014a) Three dysregulated microRNAs in serum as novel biomarkers for gastric cancer screening. Med Oncol 31(12): 1-7.
38. Wang X, Meng X, Li H, Liu W, Shen S, Gao Z (2014b) MicroRNA-25 expression level is an independent prognostic factor in epithelial ovarian cancer. Clin Transl Oncol 16(11): 954-958.
39. Wang Y, Li M, Zang W, Ma Y, Wang N, Li P, Wang T, Zhao G (2013) MiR-429 up-regulation induces apoptosis and suppresses invasion by targeting Bcl-2 and SP-1 in esophageal carcinoma. Cell Oncol (Dordr) 36(5): 385-394.
40. Xu X, Ayub B, Liu Z, Serna VA, Qiang W, Liu Y, Hernando E, Zabludoff S, Kurita T, Kong B, Wei J-J (2014) Anti-miR182 reduces ovarian cancer burden, invasion, and metastasis: an in vivo study in orthotopic xenografts of nude mice. Mol Cancer Ther 13(7): 1729-1739.
41. Ye ZB, Ma G, Zhao YH, Xiao Y, Zhan Y, Jing C, Gao K, Liu ZH, Yu SJ (2015) miR-429 inhibits migration and invasion of breast cancer cells in vitro. Int J Oncol 46(2): 531-538.
42. Yu Z, Ni L, Chen D, Zhang Q, Su Z, Wang Y, Yu W, Wu X, Ye J, Yang S, Lai Y, Li X (2013) Identification of miR-7 as an oncogene in renal cell carcinoma. J Mol Histol 44(6): 669-677.
43. Zhang H, Zuo Z, Lu X, Wang L, Wang H, Zhu Z (2012) MiR-25 regulates apoptosis by targeting Bim in human ovarian cancer. Oncol Rep 27(2): 594-598.
44. Zhou X, Hu Y, Dai L, Wang Y, Zhou J, Wang W, Di W, Qiu L (2014) MicroRNA-7 inhibits tumor metastasis and reverses epithelialmesenchymal transition through AKT/ERK1/2 inactivation by targeting EGFR in epithelial ovarian cancer. PLoS One 9(5): e96718.
45. Zhu W, He J, Chen D, Zhang B, Xu L, Ma H, Liu X, Zhang Y, Le H (2014) Expression of miR-29c, miR-93, and miR-429 as potential biomarkers for detection of early stage non-small lung cancer. PLoS One 9(2): e87780.